Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective. | Cells Tissues Organs | 2023 | 36599319 | PubTator, text mining | PubMed |
| Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors. | Proc Natl Acad Sci U S A | 2023 | 36598945 | PubTator, text mining | PubMed |
| Bidirectional Mendelian Randomisation Analysis Provides Evidence for the Causal Involvement of Dysregulation of CXCL9, CCL11 and CASP8 in the Pathogenesis of Ulcerative Colitis. | J Crohns Colitis | 2023 | 36576886 | PubTator, text mining | PubMed |
| Impact of BSG/CD147 gene expression on diagnostic, prognostic and therapeutic strategies towards malignant cancers and possible susceptibility to SARS-CoV-2. | Mol Biol Rep | 2023 | 36574092 | PubTator, text mining | PubMed |
| Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? | J Cancer Res Clin Oncol | 2023 | 36564524 | PubTator, text mining | PubMed |
| Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia. | Int J Cancer | 2023 | 36533670 | PubTator, text mining | PubMed |
| Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line. | Clin Exp Med | 2023 | 36527513 | PubTator, text mining | PubMed |
| Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease. | Blood Adv | 2023 | 36508281 | PubTator, text mining | PubMed |
| Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy. | Cancer Gene Ther | 2023 | 36494582 | PubTator, text mining | PubMed |
| Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines. | Strahlenther Onkol | 2023 | 36480032 | PubTator, text mining | PubMed |
| X-ray-irradiated K562 feeder cells for expansion of functional CAR-T cells. | Biochem Biophys Rep | 2023 | 36478893 | PubTator, text mining | PubMed |
| Role of tumor-associated neutrophils in lung cancer (Review). | Oncol Lett | 2023 | 36419755 | PubTator, text mining | PubMed |
| Allogeneic natural killer cell therapy. | Blood | 2023 | 36416736 | PubTator, text mining | PubMed |
| Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. | Semin Immunopathol | 2023 | 36414693 | PubTator, text mining | PubMed |
| An autophagy-related gene prognostic index predicting biochemical recurrence, metastasis, and drug resistance for prostate cancer. | Asian J Androl | 2023 | 36412461 | PubTator, text mining | PubMed |
| The emerging field of oncolytic virus-based cancer immunotherapy. | Trends Cancer | 2023 | 36402738 | PubTator, text mining | PubMed |
| Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells. | J Immunother | 2023 | 36378147 | PubTator, text mining | PubMed |
| Diagnostic, prognostic, and immunological roles of CD177 in cervical cancer. | J Cancer Res Clin Oncol | 2023 | 36352147 | PubTator, text mining | PubMed |
| The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies. | Mol Cancer Ther | 2023 | 36343381 | PubTator, text mining | PubMed |
| Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis. | Clin Exp Med | 2023 | 36333526 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=31